Ying Jie, Shi Chao, Li Chuan-Sheng, Hu Li-Ping, Zhang Wei-Dong
Department of Infection, Xuyi People's Hospital, Xuyi, Jiangsu 211700, P.R. China.
Department of General Surgery, Xuyi People's Hospital, Xuyi, Jiangsu 211700, P.R. China.
Oncol Lett. 2016 Nov;12(5):3195-3198. doi: 10.3892/ol.2016.5065. Epub 2016 Aug 30.
The aim of the present study was to examine the expression and clinical significance of SOX2 in non-small cell lung carcinoma (NSCLC). Immunohistochemistry was used to detect the expression level of SOX2 in 127 cases of NSCLC. The Chi-square test was used to analyze the association of SOX2 expression and clinicopathological factors in NSCLC and para-carcinoma tissues (2.5%). The Kaplan-Meier method was applied to plot the survival curve, and the log-rank test and COX multiple regression model were applied to determine survival. SOX2 showed a high expression in 35.4% NSCLC tissues, which was significantly higher than that of the para-carcinoma tissues. The expression level of SOX2 was not associated with gender, age, smoking history or TNM stage (P>0.05), but was significantly associated with the pathological type of carcinoma. The high expression rate of SOX2 in lung squamous cell carcinoma was 50% (25/50) and in lung adenocarcinoma was 20.3% (12/59). Survival analysis indicated that the prognosis of patients with a high SOX2 expression was significantly better than those with a low SOX2 expression. The COX multiple regression analysis revealed that the expression level of SOX2 was an independent prognostic factor of patients with NSCLC (P<0.001). In conclusion, the expression of SOX2 in NSCLC tissues was upregulated, which was associated with the pathological type of carcinoma, while a high SOX2 expression mainly occurred in lung squamous cell carcinoma.
本研究旨在检测SOX2在非小细胞肺癌（NSCLC）中的表达情况及其临床意义。采用免疫组化法检测127例NSCLC组织中SOX2的表达水平。采用卡方检验分析SOX2表达与NSCLC及癌旁组织（2.5%）临床病理因素的相关性。应用Kaplan-Meier法绘制生存曲线，采用对数秩检验和COX多因素回归模型分析生存情况。结果显示，35.4%的NSCLC组织中SOX2呈高表达，显著高于癌旁组织。SOX2的表达水平与性别、年龄、吸烟史及TNM分期无关（P>0.05），但与病理类型显著相关。肺鳞癌中SOX2的高表达率为50%（25/50），肺腺癌中为20.3%（12/59）。生存分析表明，SOX2高表达患者的预后明显优于低表达患者。COX多因素回归分析显示，SOX2表达水平是NSCLC患者的独立预后因素（P<0.001）。综上所述，NSCLC组织中SOX2表达上调，与病理类型相关，且高表达主要见于肺鳞癌。
